



# NECTAR LIFESCIENCES LIMITED

Regd. Office : Vill. Saidpura, Tehsil Derabassi, Distt. Mohali (Punjab)

## Unaudited Financial Results for the Quarter ended 30.06.2010 (Rs. in Lacs)

Sr. No.	PARTICULARS	Quarter ended 30.6.2010	Quarter ended 30.6.2009	Year ended 31.3.2010
		(Unaudited)	(Unaudited)	Audited
1.	<b>Gross Sales/Income from Operations</b>	19138.07	20353.50	88582.17
	Less : Excise Duty	1013.24	1174.22	4002.26
	Net Sales / Income from Operations	18124.83	19179.28	84579.91
	Other Operating Income	79.51	90.00	409.59
	<b>Total Operating Income</b>	<b>18204.34</b>	<b>19269.28</b>	<b>84989.50</b>
2.	<b>Expenditure</b>			
	a. (Increase)/decrease in stock in trade	(332.85)	620.45	939.51
	b. Consumption of Raw Material	11520.45	11918.81	53491.67
	c. Employees Cost	876.70	773.95	3187.70
	d. Depreciation	1125.64	902.26	3874.64
	e. Other Expenditure	1653.74	1498.76	7457.01
	<b>Total Expenditure</b>	<b>14843.68</b>	<b>15714.23</b>	<b>68950.53</b>
3.	<b>Profit from Operations before Other Income, Interest &amp; Exceptional Items (1-2)</b>	<b>3360.66</b>	<b>3555.05</b>	<b>16038.97</b>
4.	Other Income	5.00	49.28	1485.73
5.	<b>Profit before Interest &amp; Exceptional Items (3+4)</b>	<b>3365.66</b>	<b>3604.33</b>	<b>17524.70</b>
6.	Interest	1276.59	1559.86	6028.44
7.	<b>Profit after Interest but before Exceptional Items (5-6)</b>	<b>2089.07</b>	<b>2044.47</b>	<b>11496.26</b>
8.	Exceptional Items	-	-	-
9.	<b>Profit from ordinary activities before tax (7+8)</b>	<b>2089.07</b>	<b>2044.47</b>	<b>11496.26</b>
10.	<b>Tax Expenses</b>			
	Current Tax	416.16	347.46	1953.51
	Mat Credit Entitlement	(110.00)	(347.46)	(725.06)
	Deferred tax	214.96	0.00	1000.20
	Excess Provision for taxation written back	0.00	0.00	70.17
11.	<b>Net Profit from ordinary activities after tax (9-10)</b>	<b>1567.95</b>	<b>2044.47</b>	<b>9197.44</b>
12.	Extraordinary Item (net of tax expense)	-	-	-
13.	<b>Net Profit for the period (11-12)</b>	<b>1567.95</b>	<b>2044.47</b>	<b>9197.44</b>
14.	Paid-up Equity Share Capital ( Face Value per share : Rs. 1/-)	2242.61	1522.61	2242.61
15.	Reserves excluding Revaluation Reserves			59855.37
16.	<b>Earnings per Share (EPS)</b>			
	Basic EPS before Extraordinary items	0.70	1.34	5.81
	Diluted EPS before Extraordinary items	0.56	0.98	4.28
	Basic EPS after Extraordinary items	0.70	1.34	5.81
	Diluted EPS after Extraordinary items	0.56	0.98	4.28
17.	<b>Public Shareholding</b>			
	- Number of Shares	126119330	54119330	126119330
	- Percentage of Shareholding	56.24	35.54	56.24
18.	<b>Promoters and Promoter Group Shareholding</b>			
	<b>a) Pledged/Encumbered</b>			
	- Number of Shares	0	0	0
	- Percentage of Shares ( as a % of the total shareholding of promoter and promoter group)	0.00	0.00	0.00
	- Percentage of Shares ( as a % of the total share capital of the company)	0.00	0.00	0.00
	<b>b) Non-encumbered</b>			
	- Number of Shares	98141640	98141640	98141640
	- Percentage of Shares ( as a % of the total shareholding of promoter and promoter group)	100.00	100.00	100.00
	- Percentage of Shares ( as a % of the total share capital of the company)	43.76	64.46	43.76

- Notes :**
- The Cash Profit in quarter under review has increased by 9% over the corresponding quarter of previous year.
  - The quarter under review sales and Yearly Audited sales does not include any Inter-Unit Sales. However, Corresponding previous quarter sales includes Inter unit sales of Rs 2390 Lacs.
  - The Company has successfully started commercial operations of the new state of art Sterile Facility due to which the provision for Depreciation has gone up to Rs.1125.64 lacs in the quarter under review from Rs.902.26 lacs in the corresponding quarter.
  - The Provision for Tax in the quarter under review includes current tax and deferred tax to the extent of Rs 521.12 lacs . However corresponding previous quarter figures did not include provision for deferred tax, which was subsequently accounted for in the audited financial results of 31st March, 2010.
  - During the quarter under review the company has successfully filed 3 International Patents for 3 major Cephalosporin Molecules through PCT route which have been published.
  - The Company has successfully completed five Audit from International customers from Europe, Asia, Africa for Formulations . The impact of which, would be long term high value and higher margin business from these customers.
  - The Company has allotted 26,000,000 equity shares on preferential basis on 20.02.2010 to non-promoters and 46,000,000 equity shares underlying Global Depository Receipts (GDRs) on 26.02.2010. After said allotments, the paid up equity capital of the company stands increased from Rs. 152,260,970/- to Rs. 224,260,970/- comprising of 224,260,970 equity shares of Re. 1/- each. This is the reason of decrease in the %age of holding of the promoters, increase in the public shareholding and decrease in EPS..
  - The company is exclusively in the pharmaceutical business segment.
  - The above financial results are on stand alone basis.
  - The above financial results were reviewed by Audit Committee on 11.08.2010 and approved by the Board in its meeting held on 11.08.2010.
  - Status of Complaints:
    - Pending at the beginning of Quarter - Nil
    - Received During the Quarter - 07
    - Disposed Off During the Quarter - 07
    - Pending at the end of Quarter - Nil

**By Order of the Board of Directors  
of Nectar Lifesciences Limited**  
Sd/-  
(Dinesh Dua)  
Chief Executive Officer & Director

**Dated: 11.08.2010**  
**Place: Chandigarh**